Annals of Oncology, 0923-7534


  1. 2019
  2. Levy, S., Aarts, M. J. B., Eskens, F. A., Keymeulen, K., Been, L., Grunhagen, D. J., ... Tesselaar, M. E. T. (2019). Avelumab for advanced Merkel cell carcinoma in the Netherlands: A nationwide survey. Annals of Oncology, 30, 537-538.
  3. Lee, D. H., Kim, D-W., Camidge, D. R., Langer, C. J., Huber, R. M., Tiseo, M., ... Ahn, M-J. (2019). Brigatinib (BRG) in Asian vs non-Asian patients (pts) with crizotinib (CRZ)-refractory ALK plus NSCLC in the phase II ALTA trial. Annals of Oncology, 30, 634-635.
  4. Creutzberg, C. L., Leon-Castillo, A., de Boer, S. M., Powell, M. E., Mileshkin, L. R., Mackay, H. J., ... Bosse, T. (2019). Molecular classification of the PORTEC-3 trial for high-risk endometrial cancer: Impact on adjuvant therapy. Annals of Oncology, 30, 899-900.
  5. Dieras, V. C., Han, H. S., Kaufman, B., Wildiers, H., Friedlander, M., Ayoub, J-P., ... Arun, B. K. (2019). Phase III study of veliparib with carboplatin and paclitaxel in HER2-negative advanced/metastatic gBRCA-associated breast cancer. Annals of Oncology, 30, 857-858.
  6. Burgers, S. A., de Gooijer, C., Cornelissen, R., Aerts, J. G., Biesma, B., Heemst, R. V., ... Stigt, J. (2019). Switch maintenance gemcitabine after first-line chemotherapy in patients with malignant mesothelioma: A multicenter open label phase II trial (NVALT19). Annals of Oncology, 30.
  7. Groenland, S. L., Van Eerden, R. A. G., Koolen, S. L., Moes, D. J. A. R., Desar, I. M. E., Touw, D. J., ... Steeghs, N. (2019). Therapeutic drug monitoring of oral anticancer drugs - preliminary results of a prospective study. Annals of Oncology, 30.
  8. Lindsay, C. R., Blackhall, F. H., Carmel, A., Gazzaniga, P., Groen, H. J. M., Krebs, M. G., ... Michiels, S. (2019). EPAC-Lung: Pooled analysis of circulating tumor cells in advanced non-small cell lung cancer. Annals of Oncology, 30 (Suppl 2), ii7.
  9. 2018
  10. van Zeijl, M. C. T., Wouters, M. W. J. M., van den Eertwegh, A. J., Aarts, M. J., van Akkooi, A. C. J., van den Berkmortel, F. W. P. J., ... Haanen, J. B. A. G. (2018). Outcomes of anti-PD1 antibodies for advanced melanoma in real-world population. Annals of Oncology, 29(Suppl.8), viii455. [1276P].
  11. van Veggel, B., van der Wekken, A., Hashemi, S., Cornelissen, R., Monkhorst, K., Heideman, D., ... De Langen, J. (2018). Osimertinib treatment for patients with EGFR exon 20 insertion positive non-small cell lung cancer. Annals of Oncology, 29(Suppl.8), viii524-viii525.
  12. ESMO Guidelines Committee and EURACAN, Casali, P. G., Abecassis, N., Bauer, S., Biagini, R., Bielack, S., ... Van der Graaf, W. (2018). Soft tissue and visceral sarcomas: ESMO-EURACAN Clinical Practice Guidelines for diagnosis, treatment and follow-up. Annals of Oncology, 29(Suppl.4), 51-67.
  13. Oosting, S., Desideri, I., Staelens, D., Caballero, C., Tribius, S., Simon, C., ... Luciani, A. (2018). Treatment patterns in elderly patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC): Results from an EORTC led survey. Annals of Oncology, 29(Suppl_8), 393-393.
  14. Honecker, F., Aparicio, J., Berney, D., Beyer, J., Bokemeyer, C., Cathomas, R., ... Horwich, A. (2018). ESMO Consensus Conference on testicular germ cell cancer: diagnosis, treatment and follow-up. Annals of Oncology, 29(8), 1658-1686.
  15. Wang, H., Agulnik, J., Kasymjanova, G., Wang, A., Jiménez, P., Cohen, V., ... Spatz, A. (2018). Cytology cell blocks are suitable for immunohistochemical testing for PD-L1 in lung cancer. Annals of Oncology, 29(6), 1417-1422.
  16. Cardoso, F., Bartlett, J. M. S., Slaets, L., van Deurzen, C. H. M., van Leeuwen-Stok, E., Porter, P., ... Giordano, S. H. (2018). Characterization of male breast cancer: Results of the EORTC 10085/TBCRC/BIG/NABCG International Male Breast Cancer Program. Annals of Oncology, 29(2), 405-417.
  17. 2017
  18. van der Velden, D. L., van Herpen, C. M. L., van Laarhoven, H. W. M., Smit, E. F., Groen, H. J. M., Willems, S. M., ... Voest, E. E. (2017). Molecular Tumor Boards: Current practice and future needs. Annals of Oncology, 28(12), 3070-3075.
  19. Cherny, N. I., Dafni, U., Bogaerts, J., Latino, N. J., Pentheroudakis, G., Douillard, J. -Y., ... de Vries, E. G. E. (2017). ESMO-Magnitude of Clinical Benefit Scale version 1.1. Annals of Oncology, 28(10), 2340-2366.
  20. Valent, P., Akin, C., Hartmann, K., George, T. I., Sotlar, K., Peter, B., ... Gotlib, J. (2017). Midostaurin: A magic bullet that blocks mast cell expansion and activation. Annals of Oncology, 28(10), 2367-2376.
Previous 1 2 3 4 Next

ID: 13479495